Kleiner Device Labs Presents e-Poster at Southern Neurosurgical Society Meeting

Meeting: "Rethinking Posterior MIS Fusion – Enabling Risk Reduction in Posterior Spinal Surgery"

Kleiner Device Labs (KDL) today announced that an e-Poster has been accepted for the Southern Neurosurgical Society’s 2024 annual conference beginning on March 7 in Orlando.  The e-Poster (#156) highlights research results of new innovations in lumbar spinal implant and grafting technologies to reduce risks from poor/insufficient graft volume and placement, surgical site infection (SSI), collateral tissue damage due to multiple instrument passes, and from extended OR time.  

Posterior approach spine fusion has a number of inherent risks to patients’ health and successful outcomes, as well assignificant frustrations for surgeons, and those became the key objectives of our re-engineering a complete interbody system,said Jeff Kleiner, MD, founder and CEO of KDL.  

Dr. Blake Burkert, of NeuroSpine Group, Eugene, Oregon, noted, I share those concerns and want to minimize risks in my own OR.  Utilizing the new system over the past year has proven to be an effective answer for my PLIF and TLIF procedures and has transformed my thinking on the posterior approach to treating spine conditions.

The company will attend the meeting and looks forward to demonstrating the new KG®2 Surge® flow-thru interbody system to surgeons. The first 50 cases with the new KG 2 Surge demonstrated an average of 10ml of bone graft delivered per disc space and an average of 8 minutes total elapsed time for trial, cage placement, grafting and release of the implant.  

The e-Poster presentation will be available at the meting and afterwards on the company’s web site.

For KG2 videos and information, please go to the company’sweb site.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”